MeSH term
Frequency | Condition_Probility | Animals | 162 | 0.0 |
*Colorectal Neoplasms/diagnosis/metabolism/pathology/therapy | 2 | 3.0 |
Humans | 1092 | 0.0 |
Base Sequence | 45 | 0.0 |
Brain/metabolism | 2 | 0.0 |
*Down-Regulation | 6 | 1.0 |
Genes, Reporter/genetics | 2 | 0.0 |
Molecular Sequence Data | 49 | 0.0 |
*Oligonucleotide Array Sequence Analysis | 2 | 1.0 |
Organ Specificity | 12 | 0.0 |
Substrate Specificity | 8 | 0.0 |
ADP-ribosyl Cyclase/*metabolism | 19 | 100.0 |
Antibodies, Monoclonal/pharmacology | 13 | 1.0 |
Antigens, CD/*metabolism | 34 | 5.0 |
Cell Line | 61 | 0.0 |
Immunohistochemistry | 38 | 0.0 |
Microscopy, Confocal | 4 | 0.0 |
Microscopy, Electron | 18 | 0.0 |
Proteins/metabolism | 2 | 0.0 |
Research Support, Non-U.S. Gov't | 664 | 0.0 |
ADP-ribosyl Cyclase/genetics | 2 | 66.0 |
Adult | 340 | 0.0 |
Aged | 204 | 0.0 |
Aged, 80 and over | 67 | 0.0 |
Antigens/chemistry | 2 | 16.0 |
Antigens, CD/genetics | 4 | 2.0 |
Cell Differentiation | 63 | 2.0 |
DNA Mutational Analysis | 5 | 0.0 |
Female | 372 | 0.0 |
Genes, Immunoglobulin/*genetics | 3 | 7.0 |
Immunoglobulin Variable Region/*genetics | 11 | 10.0 |
Leukemia, Lymphocytic, Chronic/*genetics | 2 | 9.0 |
Male | 383 | 0.0 |
Middle Aged | 296 | 0.0 |
*Mutation | 12 | 0.0 |
Prognosis | 84 | 1.0 |
Time Factors | 59 | 0.0 |
ADP-ribosyl Cyclase | 360 | 80.0 |
Antibodies, Monoclonal/analysis | 4 | 4.0 |
*Antigens, CD | 243 | 31.0 |
Antigens, Differentiation/analysis | 63 | 20.0 |
Biological Markers/analysis | 22 | 2.0 |
Immunohistochemistry/methods | 2 | 0.0 |
Membrane Glycoproteins/analysis | 5 | 1.0 |
NAD+ Nucleosidase/analysis | 23 | 53.0 |
Plasma Cells/pathology | 5 | 12.0 |
Polymerase Chain Reaction/methods | 2 | 0.0 |
Proteoglycans/analysis | 3 | 21.0 |
Antigens, Bacterial/immunology | 2 | 1.0 |
CD4-Positive T-Lymphocytes/immunology | 30 | 3.0 |
Immunoglobulin M/biosynthesis | 5 | 5.0 |
Immunologic Memory | 19 | 6.0 |
Immunophenotyping | 254 | 8.0 |
Interleukin-2/pharmacology | 6 | 1.0 |
Lymphocyte Activation | 85 | 2.0 |
Lymphocyte Cooperation | 5 | 6.0 |
Antigens, Differentiation/*metabolism | 35 | 28.0 |
Binding, Competitive | 5 | 0.0 |
Catalysis | 16 | 2.0 |
Kinetics | 34 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 194 | 0.0 |
Adolescent | 78 | 0.0 |
Case-Control Studies | 19 | 0.0 |
Child | 62 | 0.0 |
Comparative Study | 147 | 0.0 |
Flow Cytometry | 249 | 3.0 |
Infection/immunology | 2 | 6.0 |
Killer Cells, Natural/cytology/*immunology | 3 | 10.0 |
Lymphocyte Activation/*immunology | 10 | 2.0 |
Anti-HIV Agents/*therapeutic use | 6 | 1.0 |
Antigens, CD28/analysis | 3 | 8.0 |
*Antiretroviral Therapy, Highly Active | 7 | 2.0 |
CD4 Lymphocyte Count | 36 | 1.0 |
CD8-Positive T-Lymphocytes/immunology | 20 | 4.0 |
Chronic Disease | 12 | 0.0 |
Cross-Sectional Studies | 8 | 0.0 |
HIV Infections/*drug therapy/immunology/virology | 2 | 1.0 |
*HIV-1 | 21 | 2.0 |
HLA-DR Antigens/analysis | 37 | 5.0 |
Lymphocyte Activation/drug effects | 5 | 0.0 |
Lymphocyte Count | 31 | 4.0 |
T-Lymphocytes/*immunology | 35 | 1.0 |
*Chromosome Aberrations | 13 | 2.0 |
Cytogenetic Analysis | 6 | 4.0 |
Disease Progression | 38 | 1.0 |
*Genes, Immunoglobulin | 8 | 4.0 |
Genome, Human | 3 | 0.0 |
Immunoglobulin Variable Region/genetics | 7 | 6.0 |
Immunoglobulins, Heavy-Chain/genetics | 9 | 5.0 |
Mutation | 11 | 0.0 |
Survival Rate | 21 | 1.0 |
Antigens, Differentiation/*analysis | 46 | 24.0 |
Biological Markers | 34 | 2.0 |
CD8-Positive T-Lymphocytes/*chemistry | 6 | 66.0 |
Child, Preschool | 45 | 0.0 |
Disease Transmission, Vertical | 2 | 2.0 |
Infant | 26 | 0.0 |
NAD+ Nucleosidase/*analysis | 19 | 76.0 |
Predictive Value of Tests | 16 | 0.0 |
Antigens, CD/analysis | 101 | 6.0 |
Lymphocytes/*pathology | 4 | 8.0 |
Models, Biological | 12 | 0.0 |
Multivariate Analysis | 7 | 0.0 |
Retrospective Studies | 9 | 0.0 |
L-Lactate Dehydrogenase/metabolism | 2 | 1.0 |
Neoplasm Staging | 12 | 0.0 |
Tumor Markers, Biological/*metabolism | 5 | 1.0 |
beta 2-Microglobulin/metabolism | 5 | 6.0 |
Biopsy, Needle | 3 | 0.0 |
Bone Marrow Cells/cytology | 2 | 2.0 |
Coculture Techniques | 10 | 1.0 |
Colony-Forming Units Assay | 28 | 4.0 |
Follow-Up Studies | 20 | 0.0 |
Hematopoiesis | 10 | 4.0 |
Lymphoma, Non-Hodgkin/therapy | 3 | 12.0 |
Stem Cells/*cytology | 3 | 3.0 |
Transplantation, Autologous | 16 | 4.0 |
Antigens, CD27/analysis | 2 | 11.0 |
Antigens, CD45/analysis | 22 | 8.0 |
T-Lymphocyte Subsets/classification/*immunology | 3 | 33.0 |
Tumor Markers, Biological/analysis | 10 | 1.0 |
ADP-ribosyl Cyclase/*analysis | 10 | 83.0 |
Antigens, CD/*analysis | 67 | 8.0 |
Biological Markers/*analysis | 4 | 3.0 |
HIV Infections/*immunology | 24 | 5.0 |
Viral Load | 20 | 2.0 |
DNA/genetics | 3 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 16 | 0.0 |
ADP-ribosyl Cyclase/*immunology | 5 | 100.0 |
Antigens, CD/*immunology | 16 | 3.0 |
Acute Disease | 34 | 1.0 |
Antigens, CD/metabolism | 29 | 3.0 |
Bone Marrow/pathology | 31 | 7.0 |
Cell Cycle | 13 | 1.0 |
*Cell Movement | 2 | 1.0 |
Fibronectins/pharmacology | 2 | 4.0 |
Hematopoietic Stem Cell Mobilization | 5 | 5.0 |
Hematopoietic Stem Cells | 3 | 4.0 |
Phenotype | 87 | 0.0 |
Receptors, CXCR4/metabolism | 2 | 1.0 |
Antibodies, Monoclonal | 35 | 1.0 |
Bone Marrow Cells/immunology | 4 | 10.0 |
Bone Marrow Purging/*methods | 2 | 5.0 |
Cell Separation/*methods | 14 | 9.0 |
Immunomagnetic Separation | 13 | 12.0 |
Leukapheresis | 12 | 11.0 |
Mice | 97 | 0.0 |
Mice, Inbred NOD | 10 | 4.0 |
Mice, SCID | 22 | 2.0 |
Multiple Myeloma/genetics/immunology/*pathology/*therapy | 2 | 100.0 |
Antigens, Neoplasm/analysis | 14 | 4.0 |
Blood Cell Count | 5 | 2.0 |
Cell Adhesion Molecules/analysis | 6 | 3.0 |
Lymphocytes/chemistry/pathology | 2 | 25.0 |
Neoplasm Proteins/analysis | 5 | 1.0 |
Splenectomy | 3 | 4.0 |
Tumor Stem Cells/chemistry/pathology | 2 | 40.0 |
Antibodies, Monoclonal/diagnostic use | 14 | 1.0 |
Antigens, CD/*analysis/genetics | 2 | 8.0 |
B-Lymphocytes/immunology | 15 | 2.0 |
Bone Marrow/*immunology | 8 | 13.0 |
Cells, Cultured | 114 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 15 | 0.0 |
Multiple Myeloma/genetics/*immunology | 2 | 40.0 |
Tumor Cells, Cultured | 95 | 0.0 |
Tumor Markers, Biological/*analysis | 7 | 0.0 |
Doxorubicin/administration & dosage | 3 | 1.0 |
Drug Administration Schedule | 4 | 0.0 |
English Abstract | 54 | 0.0 |
Melphalan/administration & dosage | 3 | 6.0 |
Prednisolone/administration & dosage | 4 | 5.0 |
Prednisone/administration & dosage | 4 | 4.0 |
Vincristine/administration & dosage | 5 | 3.0 |
Antigens, Differentiation/metabolism | 27 | 21.0 |
Chromosome Aberrations | 16 | 2.0 |
Chromosome Deletion | 3 | 0.0 |
Diagnosis, Differential | 27 | 1.0 |
Genes, p53 | 4 | 0.0 |
NAD+ Nucleosidase/metabolism | 24 | 85.0 |
*Antigens, CD34 | 4 | 5.0 |
Cell Count | 14 | 1.0 |
Cell Division/drug effects | 23 | 0.0 |
Fetal Blood | 2 | 1.0 |
*Hematopoietic Stem Cell Transplantation | 25 | 6.0 |
Membrane Proteins/pharmacology | 2 | 4.0 |
Stem Cell Factor/pharmacology | 5 | 3.0 |
Stimulation, Chemical | 5 | 1.0 |
Thrombopoietin/pharmacology | 2 | 3.0 |
Transduction, Genetic | 2 | 0.0 |
Antineoplastic Agents/*therapeutic use | 4 | 1.0 |
Apoptosis/drug effects | 3 | 0.0 |
Biological Response Modifiers/*therapeutic use | 2 | 8.0 |
Clinical Trials | 3 | 0.0 |
Drug Screening Assays, Antitumor | 3 | 0.0 |
Multiple Myeloma/*drug therapy | 2 | 12.0 |
CD8-Positive T-Lymphocytes/immunology/metabolism | 2 | 4.0 |
Cohort Studies | 24 | 0.0 |
NAD+ Nucleosidase/*metabolism | 25 | 100.0 |
RNA, Viral/*blood | 5 | 3.0 |
*Viral Load | 6 | 3.0 |
Immunoglobulin M/*metabolism | 2 | 5.0 |
Antibodies, Monoclonal/*immunology | 4 | 0.0 |
Antigens, CD/immunology | 19 | 3.0 |
Antigens, Differentiation/immunology | 11 | 10.0 |
Antigens, Neoplasm/analysis/immunology | 2 | 15.0 |
NAD+ Nucleosidase/immunology | 5 | 62.0 |
Antigens, Differentiation/genetics/*immunology | 3 | 23.0 |
Calcium/metabolism | 24 | 1.0 |
Cytotoxicity, Immunologic | 18 | 1.0 |
Immunity, Cellular | 6 | 0.0 |
Killer Cells, Natural/*immunology | 8 | 1.0 |
Phosphotyrosine/metabolism | 4 | 0.0 |
Recombinant Proteins/immunology | 2 | 0.0 |
Signal Transduction/immunology | 5 | 1.0 |
Transfection | 22 | 0.0 |
Antigens, CD34/metabolism | 6 | 2.0 |
Cell Differentiation/physiology | 5 | 1.0 |
DNA-Binding Proteins/genetics | 4 | 0.0 |
Proto-Oncogene Proteins/genetics | 3 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 18 | 0.0 |
Stromal Cells/*cytology | 2 | 13.0 |
Transcription Factors/genetics | 2 | 0.0 |
Up-Regulation | 11 | 0.0 |
In Situ Hybridization, Fluorescence | 22 | 0.0 |
Tumor Markers, Biological/metabolism | 2 | 0.0 |
Fatal Outcome | 9 | 1.0 |
Plasma Cells/*pathology | 12 | 63.0 |
Amino Acid Sequence | 27 | 0.0 |
Antigens, Differentiation/chemistry/*metabolism | 4 | 44.0 |
Binding Sites | 10 | 0.0 |
Chromatography, High Pressure Liquid | 5 | 0.0 |
Crystallography, X-Ray | 6 | 0.0 |
Dimerization | 5 | 0.0 |
Ligands | 15 | 0.0 |
Models, Chemical | 2 | 0.0 |
Models, Molecular | 6 | 0.0 |
NAD+ Nucleosidase/chemistry/*metabolism | 2 | 100.0 |
Niacinamide/metabolism | 3 | 42.0 |
Protein Binding | 8 | 0.0 |
Protein Structure, Tertiary | 5 | 0.0 |
Sequence Alignment | 3 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 12 | 2.0 |
Treatment Outcome | 20 | 0.0 |
Antigens, Differentiation/*biosynthesis | 15 | 45.0 |
Cell Differentiation/drug effects | 22 | 2.0 |
Dexamethasone/pharmacology | 4 | 0.0 |
Dose-Response Relationship, Drug | 17 | 0.0 |
HL-60 Cells/drug effects | 2 | 9.0 |
NAD+ Nucleosidase/*biosynthesis | 6 | 85.0 |
Transcription, Genetic/drug effects | 2 | 0.0 |
Gene Frequency | 3 | 0.0 |
Leukocyte Count | 19 | 1.0 |
Lymphocyte Subsets/*classification/immunology | 2 | 66.0 |
Occupational Exposure/*adverse effects | 2 | 2.0 |
Antigens, CD/biosynthesis | 14 | 4.0 |
Antigens, CD4/biosynthesis | 3 | 3.0 |
Antigens, Differentiation, B-Lymphocyte/biosynthesis | 2 | 6.0 |
Antineoplastic Agents/therapeutic use | 6 | 2.0 |
B-Lymphocytes/metabolism | 4 | 2.0 |
Bone Marrow Cells/*cytology | 5 | 10.0 |
*Cell Adhesion Molecules | 3 | 1.0 |
Flow Cytometry/*methods | 21 | 9.0 |
*Integrin alpha Chains | 2 | 7.0 |
*Lectins | 3 | 1.0 |
Lymphocyte Subsets/*cytology | 4 | 17.0 |
Macrophage-1 Antigen/biosynthesis | 3 | 11.0 |
Receptors, Interleukin-2/biosynthesis | 3 | 2.0 |
B-Lymphocytes/*immunology | 24 | 2.0 |
Disease-Free Survival | 10 | 1.0 |
Genetic Markers | 3 | 0.0 |
Leukemia, B-Cell, Chronic/genetics/*immunology | 3 | 37.0 |
Proportional Hazards Models | 7 | 1.0 |
Risk | 2 | 0.0 |
Somatic Hypermutation, Immunoglobulin | 4 | 36.0 |
Statistics, Nonparametric | 11 | 1.0 |
Antigens, CD20/*metabolism | 3 | 33.0 |
Apoptosis/immunology | 6 | 6.0 |
B-Lymphocytes/cytology/*immunology | 3 | 4.0 |
Immunoglobulin D/*metabolism | 2 | 50.0 |
Immunoglobulins, Surface/metabolism | 3 | 15.0 |
In Vitro | 30 | 0.0 |
Antigens, Differentiation/*immunology | 25 | 18.0 |
Gene Deletion | 5 | 0.0 |
Leukemia, Lymphocytic, Chronic/*genetics/*immunology/mortality | 2 | 100.0 |
NAD+ Nucleosidase/*immunology | 12 | 85.0 |
B-Lymphocyte Subsets/*immunology | 13 | 16.0 |
Chromosomes, Human, Pair 12 | 6 | 3.0 |
Cluster Analysis | 3 | 1.0 |
Trisomy | 5 | 4.0 |
Tumor Stem Cells/*immunology | 2 | 8.0 |
Antibodies, Monoclonal/immunology/*pharmacology | 2 | 4.0 |
Apoptosis/*physiology | 4 | 0.0 |
B-Lymphocytes/*cytology | 6 | 9.0 |
Blotting, Western | 16 | 0.0 |
Severity of Illness Index | 4 | 0.0 |
Signal Transduction | 27 | 0.0 |
Antigens, Neoplasm/*analysis | 9 | 2.0 |
Hemoglobins/analysis | 2 | 0.0 |
Life Tables | 3 | 1.0 |
Platelet Count | 2 | 0.0 |
Risk Factors | 7 | 0.0 |
Survival Analysis | 23 | 1.0 |
Cell Adhesion/drug effects | 4 | 0.0 |
Interferons/pharmacology | 2 | 2.0 |
B-Lymphocytes/*chemistry | 2 | 9.0 |
Fluorescent Antibody Technique, Indirect | 7 | 0.0 |
Remission Induction | 8 | 1.0 |
DNA Primers | 10 | 0.0 |
Proto-Oncogene Proteins/*genetics | 3 | 0.0 |
Recombinant Fusion Proteins/metabolism | 6 | 0.0 |
Antigens, Neoplasm/*metabolism | 3 | 3.0 |
Fluorescence | 2 | 0.0 |
Antigens, Differentiation/*blood | 8 | 44.0 |
Biological Markers/blood | 18 | 1.0 |
Genes, Immunoglobulin | 7 | 3.0 |
Leukemia, B-Cell, Chronic/*diagnosis/genetics/immunology | 3 | 75.0 |
NAD+ Nucleosidase/*blood | 7 | 77.0 |
Reproducibility of Results | 10 | 0.0 |
Hematopoietic Stem Cells/*cytology/immunology | 13 | 15.0 |
L-Selectin/analysis | 4 | 20.0 |
Macrophage-1 Antigen/analysis | 2 | 4.0 |
Receptors, Cell Surface/*analysis | 2 | 1.0 |
Antigens, CD19/analysis | 8 | 9.0 |
Antigens, CD95/*analysis | 2 | 9.0 |
CD4-Positive T-Lymphocytes/chemistry/immunology | 2 | 20.0 |
Lupus Erythematosus, Systemic/*immunology | 2 | 1.0 |
Immunophenotyping/methods | 6 | 12.0 |
*Cytotoxicity, Immunologic | 9 | 1.0 |
*Lymphocyte Activation | 38 | 2.0 |
Membrane Glycoproteins/*physiology | 4 | 1.0 |
Immunoglobulin D/analysis | 2 | 9.0 |
Immunoglobulin M/analysis | 3 | 1.0 |
Bleomycin/administration & dosage | 2 | 2.0 |
Methotrexate/administration & dosage | 2 | 2.0 |
Multiple Myeloma/drug therapy/*pathology | 2 | 50.0 |
Reference Values | 23 | 0.0 |
Antigens, CD34/*analysis | 21 | 7.0 |
Cell Division/physiology | 11 | 1.0 |
Granulocyte Colony-Stimulating Factor/pharmacology | 10 | 6.0 |
Proto-Oncogene Protein c-kit/metabolism | 2 | 4.0 |
Antigens, CD34/analysis | 31 | 4.0 |
Breast Neoplasms/therapy | 2 | 13.0 |
Cell Lineage | 15 | 3.0 |
Hematopoietic Stem Cells/cytology/immunology | 6 | 18.0 |
Prospective Studies | 10 | 0.0 |
Cytokines/*biosynthesis | 4 | 1.0 |
Infant, Newborn | 42 | 0.0 |
Interferon Type II/biosynthesis | 6 | 1.0 |
Interleukin-6/biosynthesis | 4 | 1.0 |
Liver/*metabolism | 2 | 0.0 |
Tumor Necrosis Factor-alpha/biosynthesis | 3 | 0.0 |
Antigens, CD11/analysis | 2 | 6.0 |
Antigens, CD44/analysis | 2 | 2.0 |
Antigens, Differentiation, T-Lymphocyte/analysis | 12 | 3.0 |
Lymphocytes/*immunology | 13 | 3.0 |
Tumor Necrosis Factor-alpha/analysis | 3 | 0.0 |
Chromosomes, Human, Pair 22 | 3 | 1.0 |
Chromosomes, Human, Pair 8 | 3 | 2.0 |
DNA Primers/chemistry | 2 | 0.0 |
DNA, Neoplasm/analysis | 8 | 1.0 |
Immunoenzyme Techniques | 12 | 0.0 |
Karyotyping | 39 | 2.0 |
Polymerase Chain Reaction | 30 | 0.0 |
*CD4 Lymphocyte Count | 4 | 1.0 |
HIV Infections/*drug therapy/*immunology/virology | 6 | 18.0 |
RNA, Viral/blood | 13 | 2.0 |
Viremia/drug therapy/immunology/virology | 2 | 22.0 |
Virus Replication/drug effects | 4 | 1.0 |
Antigens, Neoplasm/*biosynthesis | 2 | 6.0 |
B-Lymphocytes/cytology | 5 | 6.0 |
CD4-CD8 Ratio | 13 | 2.0 |
Ethiopia | 2 | 7.0 |
*Genetic Vectors | 4 | 1.0 |
Green Fluorescent Proteins | 5 | 0.0 |
Leukemia, Erythroblastic, Acute/pathology | 2 | 6.0 |
Luminescent Proteins/genetics | 3 | 1.0 |
Cycloheximide/pharmacology | 2 | 0.0 |
Down-Regulation | 16 | 0.0 |
Monocytes/*metabolism | 3 | 0.0 |
NAD/*metabolism | 4 | 28.0 |
Protein Synthesis Inhibitors/pharmacology | 2 | 0.0 |
Blood Glucose/metabolism | 2 | 0.0 |
Cell Separation | 50 | 4.0 |
DNA, Complementary/metabolism | 2 | 0.0 |
Disulfides | 2 | 2.0 |
Hela Cells | 6 | 0.0 |
Mice, Inbred BALB C | 12 | 0.0 |
Mutagenesis, Site-Directed | 6 | 0.0 |
Oligonucleotides, Antisense/pharmacology | 2 | 0.0 |
Blotting, Northern | 7 | 0.0 |
Blotting, Southern | 14 | 0.0 |
Chromosomes, Human, Pair 14 | 5 | 3.0 |
Chromosomes, Human, Pair 3 | 2 | 1.0 |
Cloning, Molecular | 15 | 0.0 |
Multiple Myeloma/genetics/immunology/*pathology | 3 | 60.0 |
Sequence Homology, Nucleic Acid | 3 | 0.0 |
Translocation, Genetic | 8 | 1.0 |
Antibodies/pharmacology | 4 | 1.0 |
Cell Movement/drug effects | 2 | 0.0 |
ADP-ribosyl Cyclase/metabolism | 12 | 80.0 |
Cell Communication | 5 | 1.0 |
Cell Division | 61 | 1.0 |
Solubility | 10 | 0.0 |
Cytokines/blood | 4 | 1.0 |
Antigens, CD/*physiology | 5 | 1.0 |
Mice, Inbred Strains | 2 | 0.0 |
Mice, Knockout | 2 | 0.0 |
Tumor Necrosis Factor-alpha/pharmacology | 5 | 0.0 |
RNA, Messenger/metabolism | 10 | 0.0 |
Recurrence | 11 | 0.0 |
Antiretroviral Therapy, Highly Active | 9 | 2.0 |
*Apoptosis | 13 | 0.0 |
CD4-Positive T-Lymphocytes/*physiology | 2 | 2.0 |
HIV Infections/*drug therapy/immunology | 4 | 3.0 |
HIV-1/physiology | 3 | 3.0 |
Interleukin-2/*administration & dosage | 2 | 7.0 |
Receptors, Interleukin-2/metabolism | 4 | 2.0 |
Antigens, CD27/metabolism | 3 | 23.0 |
Antigens, CD95/metabolism | 2 | 1.0 |
Arthritis, Rheumatoid/immunology | 2 | 2.0 |
B-Lymphocyte Subsets/*classification/*immunology | 2 | 100.0 |
Germinal Center/*immunology | 2 | 33.0 |
Immunoglobulin Class Switching | 2 | 10.0 |
Immunoglobulin D/metabolism | 2 | 22.0 |
Tonsil/immunology | 3 | 4.0 |
CD4-Positive T-Lymphocytes/*immunology | 17 | 2.0 |
HIV Infections/drug therapy/*immunology/virology | 4 | 10.0 |
HLA-DR Antigens/metabolism | 10 | 7.0 |
T-Lymphocyte Subsets/classification | 3 | 25.0 |
HL-60 Cells | 27 | 4.0 |
B-Lymphocytes/*metabolism | 4 | 2.0 |
Herpesvirus 4, Human/*genetics | 3 | 4.0 |
Antigens, CD/blood | 17 | 7.0 |
Antigens, CD34/blood | 2 | 3.0 |
Cell Culture Techniques/methods | 4 | 1.0 |
Culture Media | 2 | 0.0 |
Granulocyte Colony-Stimulating Factor/*therapeutic use | 5 | 8.0 |
Hematopoietic Stem Cell Mobilization/*methods | 7 | 13.0 |
Hematopoietic Stem Cell Transplantation/*methods | 5 | 5.0 |
Hematopoietic Stem Cells/*cytology | 14 | 6.0 |
Neoplasms/*therapy | 2 | 1.0 |
Lymphocytes/immunology/*metabolism | 3 | 12.0 |
Fetus | 3 | 0.0 |
Pregnancy | 28 | 0.0 |
Leukocytes, Mononuclear/metabolism | 5 | 2.0 |
Antigens, CD34/*immunology | 8 | 10.0 |
Antigens, CD57 | 5 | 7.0 |
Antigens, Differentiation | 11 | 14.0 |
HLA-DR Antigens | 2 | 0.0 |
Immune Tolerance | 3 | 1.0 |
NAD+ Nucleosidase | 5 | 38.0 |
*T-Lymphocyte Subsets | 3 | 4.0 |
*Antibodies, Monoclonal | 3 | 1.0 |
Antibody Specificity | 7 | 0.0 |
Cell Separation/methods | 5 | 3.0 |
Cryopreservation | 5 | 4.0 |
Jurkat Cells | 17 | 1.0 |
Cytokines/secretion | 2 | 2.0 |
Cytotoxicity Tests, Immunologic | 6 | 1.0 |
Herpesvirus 4, Human/*immunology | 4 | 5.0 |
*Immunologic Memory | 3 | 2.0 |
*Immunophenotyping | 17 | 9.0 |
Adenosine Diphosphate Ribose/analogs & derivatives/metabolism | 8 | 100.0 |
Calcium Signaling/drug effects/*physiology | 2 | 11.0 |
Chelating Agents/pharmacology | 2 | 2.0 |
Cyclic ADP-Ribose | 31 | 86.0 |
Enzyme Activation/drug effects | 2 | 0.0 |
Enzyme Inhibitors/pharmacology | 7 | 0.0 |
Fluorescent Dyes | 5 | 1.0 |
Ryanodine/pharmacology | 4 | 50.0 |
Antigens, CD45/*immunology | 5 | 15.0 |
Cell Differentiation/*immunology | 2 | 7.0 |
Cell Division/immunology | 8 | 2.0 |
Fetal Blood/immunology | 2 | 2.0 |
Antigens, CD3/immunology/metabolism | 2 | 11.0 |
Antibodies, Monoclonal/*pharmacology | 2 | 1.0 |
Antibody Formation | 7 | 1.0 |
Antigens, Differentiation, B-Lymphocyte/*immunology | 5 | 6.0 |
Epitopes/immunology | 2 | 0.0 |
Immunotherapy | 4 | 1.0 |
Papio | 2 | 1.0 |
Plasma Cells/*immunology | 16 | 57.0 |
CD8-Positive T-Lymphocytes/*immunology | 28 | 8.0 |
Cell Culture Techniques | 8 | 1.0 |
Lymphocyte Activation/immunology | 14 | 2.0 |
T-Lymphocyte Subsets/*immunology | 25 | 4.0 |
Up-Regulation/*immunology | 2 | 3.0 |
Antigens, CD45/biosynthesis | 2 | 3.0 |
Antigens, CD95/biosynthesis | 4 | 13.0 |
Antigens, Differentiation/biosynthesis | 11 | 21.0 |
CD4-Positive T-Lymphocytes/metabolism | 4 | 3.0 |
CD8-Positive T-Lymphocytes/metabolism | 2 | 2.0 |
HIV Seropositivity/*immunology | 2 | 2.0 |
NAD+ Nucleosidase/biosynthesis | 4 | 57.0 |
Gene Expression Regulation/drug effects | 6 | 0.0 |
Glycosylation | 2 | 0.0 |
Protein Conformation | 6 | 0.0 |
Recombinant Proteins/chemistry/metabolism | 3 | 0.0 |
Tunicamycin/pharmacology | 2 | 2.0 |
Family Health | 2 | 0.0 |
Nuclear Family | 2 | 0.0 |
Analysis of Variance | 5 | 0.0 |
Leukemia, B-Cell, Chronic/*diagnosis | 2 | 50.0 |
Antigens, CD45/metabolism | 3 | 3.0 |
Receptors, CCR5/*metabolism | 2 | 1.0 |
Receptors, CXCR4/*metabolism | 2 | 1.0 |
Herpesvirus 4, Human/genetics/isolation & purification | 3 | 23.0 |
B-Lymphocytes/pathology | 2 | 2.0 |
Clone Cells | 12 | 1.0 |
Gene Rearrangement | 13 | 2.0 |
Antigens, Differentiation, B-Lymphocyte/analysis | 16 | 9.0 |
Immunophenotyping/*methods | 5 | 7.0 |
*Cell Cycle | 2 | 0.0 |
DNA/*analysis | 2 | 0.0 |
Immunophenotyping/*standards | 3 | 25.0 |
Plasma Cells/chemistry/*pathology | 2 | 100.0 |
Leukocytes, Mononuclear/immunology | 11 | 4.0 |
Longitudinal Studies | 5 | 0.0 |
Antigens, CD56/*analysis | 4 | 12.0 |
Antigens, CD7/*analysis | 3 | 12.0 |
DNA, Viral/analysis | 3 | 0.0 |
Herpesvirus 8, Human/genetics | 2 | 28.0 |
DNA, Complementary | 4 | 0.0 |
Drug Resistance, Neoplasm | 4 | 0.0 |
3T3 Cells | 6 | 0.0 |
Calcium/*metabolism | 16 | 2.0 |
Enterotoxins/pharmacology | 2 | 3.0 |
Insulin/*secretion | 5 | 6.0 |
Islets of Langerhans/drug effects/*physiology/secretion | 2 | 40.0 |
Superantigens/pharmacology | 2 | 8.0 |
T-Lymphocytes/immunology | 16 | 1.0 |
Antigens, CD/*blood | 10 | 5.0 |
Antigens, CD45/blood | 3 | 12.0 |
Antigens, Differentiation/blood | 3 | 27.0 |
Genes, MHC Class I | 2 | 1.0 |
Genotype | 7 | 0.0 |
HLA-DR Antigens/blood | 4 | 7.0 |
*Membrane Proteins | 3 | 0.0 |
NAD+ Nucleosidase/blood | 3 | 60.0 |
Regression Analysis | 4 | 0.0 |
*Earth (Planet) | 2 | 13.0 |
Electromagnetic Fields/adverse effects | 2 | 13.0 |
*Nature | 2 | 13.0 |
*Sleep | 2 | 8.0 |
Gene Rearrangement, T-Lymphocyte | 2 | 1.0 |
Cell Survival | 7 | 0.0 |
*Gene Transfer Techniques | 5 | 1.0 |
Genes, Reporter | 3 | 0.0 |
Hematopoietic Stem Cells/cytology/*immunology | 3 | 6.0 |
Antigens, CD34/*metabolism | 5 | 4.0 |
Culture Media, Serum-Free/pharmacology | 2 | 1.0 |
Fetal Blood/cytology | 14 | 7.0 |
Hematopoietic Stem Cells/*cytology/*immunology | 4 | 16.0 |
Antigens, Differentiation/*physiology | 9 | 10.0 |
Gene Expression Regulation/physiology | 2 | 0.0 |
Hematopoietic Stem Cells/*physiology | 2 | 1.0 |
NAD+ Nucleosidase/*physiology | 4 | 100.0 |
Antigens, Differentiation/biosynthesis/genetics/immunology/*physiology | 2 | 100.0 |
Enzyme Induction/drug effects | 3 | 0.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology | 10 | 2.0 |
Interferon Type II/*pharmacology | 2 | 0.0 |
Interleukin-10/pharmacology | 3 | 4.0 |
Interleukin-4/pharmacology | 4 | 1.0 |
Lipopolysaccharides/pharmacology | 2 | 0.0 |
NAD+ Nucleosidase/biosynthesis/genetics/immunology/*physiology | 2 | 100.0 |
Recombinant Proteins/pharmacology | 13 | 0.0 |
Umbilical Veins | 2 | 0.0 |
HIV Seropositivity | 3 | 2.0 |
HIV-1/genetics/*immunology | 2 | 2.0 |
*Prostitution | 2 | 11.0 |
NAD+ Nucleosidase/genetics/*immunology | 2 | 100.0 |
Sensitivity and Specificity | 5 | 0.0 |
Antigens, CD3/analysis | 3 | 1.0 |
Histocompatibility Antigens Class II/analysis | 2 | 1.0 |
Interferon Type II/analysis | 2 | 2.0 |
Phosphorylation | 19 | 0.0 |
Protein-Tyrosine Kinase/analysis/metabolism | 2 | 33.0 |
Proto-Oncogene Proteins/analysis | 2 | 1.0 |
RNA, Messenger/analysis | 8 | 0.0 |
Receptors, IgE/analysis | 3 | 10.0 |
Receptors, Interleukin-2/analysis | 15 | 5.0 |
Tyrosine/metabolism | 8 | 0.0 |
*Gene Expression Regulation, Neoplastic | 3 | 0.0 |
Leukemia, T-Cell, Acute/pathology | 3 | 8.0 |
RNA, Messenger/biosynthesis | 5 | 0.0 |
Antigens, Differentiation/chemistry/genetics/*metabolism | 2 | 33.0 |
Hydrolysis | 10 | 1.0 |
NAD+ Nucleosidase/chemistry/genetics/*metabolism | 2 | 100.0 |
Pichia/genetics | 2 | 7.0 |
Adenosine Diphosphate Ribose/*physiology | 2 | 100.0 |
Calcium Signaling/*physiology | 3 | 6.0 |
Antibodies, Monoclonal/immunology/pharmacology | 3 | 3.0 |
*Membrane Glycoproteins | 4 | 0.0 |
Antibodies, Monoclonal/metabolism | 7 | 2.0 |
Antigens, CD31/*metabolism | 4 | 36.0 |
Antigens, Differentiation/genetics/*metabolism | 4 | 16.0 |
Cytokines/metabolism | 4 | 0.0 |
Isoenzymes/metabolism | 2 | 0.0 |
NAD+ Nucleosidase/genetics/*metabolism | 2 | 100.0 |
Phospholipase C/metabolism | 3 | 1.0 |
Precipitin Tests | 8 | 0.0 |
Signal Transduction/*physiology | 4 | 0.0 |
T-Lymphocyte Subsets/*metabolism | 2 | 6.0 |
Antigens, CD/physiology | 3 | 1.0 |
Bone Marrow Cells/immunology/metabolism | 2 | 15.0 |
Hematopoietic Stem Cells/immunology/*metabolism | 5 | 27.0 |
Antigens, CD/biosynthesis/immunology | 3 | 10.0 |
HIV Infections/drug therapy/*immunology | 5 | 7.0 |
*Tumor Cells, Cultured | 6 | 8.0 |
Cell Nucleus/pathology | 2 | 2.0 |
*Flow Cytometry | 12 | 7.0 |
Glycoproteins/analysis | 2 | 3.0 |
Fusion Proteins, bcr-abl/*genetics | 4 | 5.0 |
*Gene Rearrangement | 4 | 1.0 |
Chromosomes, Human, Pair 11/*genetics | 3 | 1.0 |
Databases, Factual | 2 | 0.0 |
Japan | 4 | 0.0 |
*Carrier Proteins | 2 | 0.0 |
Disease Models, Animal | 5 | 0.0 |
Drug Therapy, Combination | 13 | 0.0 |
Immunoglobulin G/immunology | 5 | 1.0 |
*N-Glycosyl Hydrolases | 3 | 5.0 |
*RNA-Binding Proteins | 2 | 0.0 |
Antigens, CD34 | 57 | 9.0 |
Cell Proliferation | 3 | 1.0 |
Drug Interactions | 2 | 0.0 |
Bone Marrow/embryology | 5 | 20.0 |
Bone Marrow Cells/*metabolism | 3 | 6.0 |
*Cell Line, Tumor | 2 | 15.0 |
Cell Membrane/metabolism | 10 | 0.0 |
Mice, Nude | 4 | 0.0 |
S Phase | 2 | 0.0 |
Sequence Analysis, DNA | 5 | 0.0 |
U937 Cells | 2 | 0.0 |
Germinal Center/metabolism | 2 | 40.0 |
Immunoglobulin G/genetics | 2 | 5.0 |
Immunoglobulin M/genetics | 2 | 13.0 |
Tumor Markers, Biological | 6 | 1.0 |
Binding, Competitive/immunology | 2 | 2.0 |
Cell Division/drug effects/immunology | 2 | 3.0 |
Epitope Mapping | 2 | 0.0 |
CD4-Positive T-Lymphocytes/*immunology/virology | 2 | 8.0 |
Receptors, CCR5/analysis | 3 | 6.0 |
Receptors, CXCR4/analysis | 3 | 8.0 |
T-Lymphocyte Subsets/immunology | 17 | 4.0 |
Virus Replication | 6 | 0.0 |
B-Lymphocyte Subsets/cytology/immunology/metabolism | 2 | 100.0 |
Cell Differentiation/immunology | 7 | 2.0 |
Receptors, Interleukin-2/blood | 2 | 2.0 |
T-Lymphocyte Subsets | 3 | 2.0 |
Treatment Failure | 2 | 0.0 |
Gene Expression Regulation | 10 | 0.0 |
Hematopoietic Stem Cells/cytology | 4 | 4.0 |
Lymphokines/secretion | 2 | 5.0 |
Thymus Gland/*cytology | 4 | 7.0 |
Probability | 2 | 0.0 |
Apoptosis/*immunology | 8 | 4.0 |
Monocytes/metabolism | 2 | 0.0 |
Models, Immunological | 4 | 1.0 |
Antigens, CD40/immunology | 2 | 3.0 |
Intestine, Small/*immunology | 2 | 20.0 |
Peyer's Patches/immunology | 2 | 22.0 |
ADP-ribosyl Cyclase/analysis | 14 | 66.0 |
Cytokines/analysis | 2 | 2.0 |
Bone Marrow Cells/*pathology | 3 | 12.0 |
Ki-67 Antigen/analysis | 2 | 0.0 |
Stromal Cells/cytology | 3 | 6.0 |
ADP-ribosyl Cyclase/immunology | 2 | 50.0 |
Antigens, CD34/immunology | 5 | 9.0 |
CD4-Positive T-Lymphocytes/cytology/immunology | 3 | 5.0 |
CD8-Positive T-Lymphocytes/cytology/immunology | 3 | 10.0 |
Computer Simulation | 2 | 0.0 |
T-Lymphocytes/cytology/*immunology | 2 | 1.0 |
*ADP-ribosyl Cyclase | 3 | 50.0 |
*Cell Lineage | 2 | 8.0 |
Detergents/pharmacology | 2 | 1.0 |
Electrophoresis, Polyacrylamide Gel | 5 | 0.0 |
Enzyme Activation | 8 | 0.0 |
Immunoblotting | 4 | 0.0 |
Polyethylene Glycols/pharmacology | 2 | 4.0 |
Protein-Tyrosine Kinase/metabolism | 6 | 0.0 |
Tetradecanoylphorbol Acetate/metabolism | 2 | 6.0 |
Lymphocyte Subsets/immunology | 8 | 5.0 |
Caspases/metabolism | 2 | 0.0 |
B-Lymphocytes/*immunology/virology | 2 | 25.0 |
Immunoglobulin A/analysis | 3 | 1.0 |
Immunoglobulin G/analysis | 6 | 1.0 |
Interleukin-6/*pharmacology | 3 | 1.0 |
Multiple Myeloma/immunology/*pathology | 2 | 33.0 |
B-Lymphocytes/*physiology | 6 | 4.0 |
Tonsil/cytology | 8 | 9.0 |
Fluorescent Antibody Technique | 30 | 1.0 |
Neoplasm, Residual | 3 | 3.0 |
Chromosome Banding | 3 | 0.0 |
*Chromosomes, Human, Pair 14 | 2 | 1.0 |
Immunoglobulins, Heavy-Chain/*genetics | 8 | 5.0 |
*In Situ Hybridization, Fluorescence | 2 | 1.0 |
*Translocation, Genetic | 5 | 0.0 |
Herpesvirus 4, Human/isolation & purification | 4 | 6.0 |
Nucleic Acid Hybridization | 4 | 0.0 |
Genes, MHC Class II | 2 | 0.0 |
Histocompatibility Antigens Class I/analysis | 2 | 2.0 |
Receptors, Interleukin-6/analysis | 2 | 33.0 |
Flow Cytometry/methods | 11 | 4.0 |
B-Lymphocytes/*pathology | 5 | 11.0 |
Tumor Stem Cell Assay | 7 | 3.0 |
Antigens, CD34/*blood | 6 | 8.0 |
Down-Regulation/*drug effects | 2 | 3.0 |
Granulocyte Colony-Stimulating Factor/*pharmacology | 8 | 6.0 |
Integrin alpha4beta1 | 3 | 3.0 |
Transplantation, Homologous | 3 | 0.0 |
Acquired Immunodeficiency Syndrome/*immunology | 3 | 1.0 |
HIV-1 | 5 | 2.0 |
Multienzyme Complexes/metabolism | 2 | 1.0 |
Microscopy, Fluorescence | 4 | 0.0 |
Rabbits | 3 | 0.0 |
Rats | 11 | 0.0 |
Sequence Homology, Amino Acid | 13 | 0.0 |
Antigens, CD13/*analysis | 2 | 40.0 |
Antigens, Differentiation, Myelomonocytic/*analysis | 3 | 2.0 |
Cytogenetics | 2 | 2.0 |
*Antigens, Differentiation | 3 | 3.0 |
*NAD+ Nucleosidase | 2 | 100.0 |
Antigens, CD/*analysis/immunology | 2 | 6.0 |
HIV Infections/*immunology/virology | 3 | 4.0 |
Receptors, Tumor Necrosis Factor/blood | 2 | 2.0 |
Receptors, Tumor Necrosis Factor, Type II | 2 | 0.0 |
Tumor Necrosis Factor-alpha/metabolism | 2 | 0.0 |
Apoptosis | 16 | 0.0 |
Multienzyme Complexes/*physiology | 4 | 21.0 |
Antigens, Differentiation/analysis/*physiology | 3 | 50.0 |
B-Lymphocytes/physiology | 2 | 3.0 |
*Hematopoiesis | 6 | 3.0 |
NAD+ Nucleosidase/analysis/*physiology | 3 | 100.0 |
Antibodies, Monoclonal/immunology | 30 | 1.0 |
T-Lymphocytes/*physiology | 3 | 1.0 |
Antigens, Differentiation/chemistry/*physiology | 2 | 40.0 |
Biological Transport | 7 | 0.0 |
Homeostasis | 4 | 1.0 |
NAD/pharmacology | 2 | 14.0 |
Protein Structure, Secondary | 2 | 0.0 |
Antigens, Differentiation/*genetics | 9 | 6.0 |
Gene Expression Regulation/*drug effects | 2 | 0.0 |
Leukemia, Promyelocytic, Acute/drug therapy | 2 | 50.0 |
Multienzyme Complexes/*genetics | 3 | 4.0 |
NAD+ Nucleosidase/*genetics | 4 | 80.0 |
Anti-HIV Agents/pharmacology/*therapeutic use | 2 | 6.0 |
Cytokines/biosynthesis | 5 | 0.0 |
HIV-1/*immunology/physiology | 2 | 5.0 |
Vascular Cell Adhesion Molecule-1/metabolism | 2 | 2.0 |
Fetal Blood/cytology/*immunology | 3 | 15.0 |
Cell Transformation, Viral | 4 | 1.0 |
DNA, Neoplasm/genetics | 2 | 0.0 |
Gene Expression Regulation, Neoplastic | 4 | 0.0 |
Gene Rearrangement, B-Lymphocyte | 5 | 9.0 |
Open Reading Frames | 2 | 0.0 |
Bone Marrow/*metabolism | 2 | 4.0 |
Histocytochemistry | 4 | 0.0 |
Antigens, Differentiation/*chemistry | 4 | 50.0 |
Cysteine/metabolism | 3 | 3.0 |
Dithiothreitol/pharmacology | 3 | 3.0 |
NAD/metabolism | 12 | 19.0 |
NAD+ Nucleosidase/*chemistry | 2 | 100.0 |
Fetal Blood/*cytology | 19 | 9.0 |
Neoplasm Transplantation | 5 | 0.0 |
Annexin A5/metabolism | 4 | 4.0 |
Anti-HIV Agents/therapeutic use | 8 | 3.0 |
Staining and Labeling | 7 | 1.0 |
Cell Adhesion Molecules/*analysis | 2 | 1.0 |
Integrins/analysis | 2 | 4.0 |
Gene Expression | 16 | 0.0 |
Leukemia, Lymphocytic, Chronic/genetics/*immunology | 2 | 50.0 |
Amino Acid Substitution | 2 | 0.0 |
Antigens, CD/chemistry/metabolism | 2 | 20.0 |
Aplysia/enzymology | 11 | 91.0 |
*Signal Transduction | 10 | 0.0 |
Membrane Glycoproteins/*blood | 3 | 5.0 |
HLA-DR Antigens/immunology | 11 | 5.0 |
*Lymphocyte Subsets | 3 | 3.0 |
Adenosine Diphosphate Ribose/*analogs & derivatives/metabolism | 4 | 66.0 |
Sea Urchins | 4 | 20.0 |
Signal Transduction/physiology | 4 | 0.0 |
T-Lymphocytes/physiology | 2 | 1.0 |
Intracellular Fluid/metabolism | 2 | 1.0 |
Second Messenger Systems | 2 | 2.0 |
Cell Cycle/physiology | 4 | 1.0 |
Interleukin-2/metabolism | 3 | 2.0 |
Antigens, CD | 11 | 8.0 |
Cytosol/metabolism | 2 | 0.0 |
Antigens, Surface/*analysis | 8 | 4.0 |
Bone Marrow Cells/*immunology | 2 | 7.0 |
Hematopoietic Stem Cells/*immunology | 19 | 13.0 |
Antigens, Differentiation/*biosynthesis/immunology | 2 | 66.0 |
Monocytes/immunology/*metabolism | 2 | 4.0 |
NAD+ Nucleosidase/*biosynthesis/immunology | 2 | 100.0 |
Proto-Oncogene Proteins/metabolism | 5 | 0.0 |
T-Lymphocytes/metabolism | 7 | 2.0 |
*Ubiquitin-Protein Ligases | 6 | 1.0 |
Combined Modality Therapy | 10 | 0.0 |
Graft Survival | 7 | 1.0 |
Hematopoietic Stem Cell Transplantation/methods | 2 | 11.0 |
Leukapheresis/methods | 2 | 12.0 |
Edetic Acid/pharmacology | 2 | 1.0 |
Indicators and Reagents | 2 | 0.0 |
Integrins/metabolism | 2 | 1.0 |
Tonsil/*cytology/immunology | 2 | 25.0 |
Antigens, Differentiation/genetics | 2 | 6.0 |
DNA Primers/genetics | 5 | 0.0 |
DNA-Binding Proteins/*genetics | 3 | 0.0 |
Mice, Inbred C57BL | 5 | 0.0 |
Transcription Factors/*genetics | 2 | 0.0 |
Calcium Signaling | 2 | 2.0 |
Monocytes/*immunology | 3 | 0.0 |
Calcium/blood | 3 | 1.0 |
Cross-Linking Reagents | 2 | 0.0 |
Immunoglobulin M/*blood | 2 | 5.0 |
Leukemia, B-Cell, Chronic/*immunology/*pathology | 2 | 40.0 |
Necrosis | 3 | 0.0 |
Leukemia, Myeloid/*immunology | 2 | 5.0 |
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage | 2 | 3.0 |
Recombinant Proteins/metabolism | 4 | 0.0 |
Transcription, Genetic | 6 | 0.0 |
Antigens, Differentiation/genetics/*physiology | 3 | 18.0 |
NAD+ Nucleosidase/genetics/*physiology | 2 | 100.0 |
Peroxidase/analysis | 2 | 3.0 |
Ploidies | 6 | 2.0 |
Recombinant Proteins/biosynthesis | 4 | 0.0 |
Culture Media, Conditioned/pharmacology | 2 | 1.0 |
Interferon Type II/pharmacology | 7 | 1.0 |
Biological Assay | 3 | 1.0 |
Cattle | 4 | 0.0 |
Retroviridae | 2 | 2.0 |
DNA, Complementary/genetics | 2 | 0.0 |
HIV Infections/drug therapy/*immunology/*virology | 3 | 37.0 |
*Virus Replication | 2 | 0.0 |
Age of Onset | 2 | 0.0 |
Antigens, CD20/metabolism | 2 | 9.0 |
ADP-ribosyl Cyclase/*genetics/immunology | 2 | 100.0 |
Antigens, CD/*genetics/immunology | 2 | 11.0 |
Genetic Predisposition to Disease | 2 | 0.0 |
*Drug Resistance | 2 | 4.0 |
Fetal Blood/*immunology | 4 | 5.0 |
Antigens, CD34/*blood/immunology | 2 | 66.0 |
Fetal Blood/*cytology/immunology | 9 | 39.0 |
Immunomagnetic Separation/methods | 2 | 18.0 |
Stem Cells/cytology/immunology | 2 | 11.0 |
Interleukin-2/immunology | 5 | 4.0 |
T-Lymphocytes, Cytotoxic/immunology | 4 | 1.0 |
Antibodies, Monoclonal/*therapeutic use | 3 | 0.0 |
Antigens, CD20/biosynthesis | 2 | 11.0 |
Cell Fractionation | 4 | 1.0 |
Erythroid Progenitor Cells/pathology | 2 | 8.0 |
Multiple Myeloma/*pathology | 11 | 18.0 |
Propidium | 2 | 8.0 |
Blood Component Removal | 2 | 4.0 |
Evaluation Studies | 2 | 0.0 |
HIV Infections/blood/*immunology | 4 | 6.0 |
HIV-1/*immunology | 13 | 2.0 |
Mitogens/pharmacology | 3 | 1.0 |
Phytohemagglutinins/pharmacology | 2 | 0.0 |
Biopsy | 4 | 0.0 |
T-Lymphocyte Subsets/*immunology/metabolism | 3 | 6.0 |
Tonsil | 2 | 9.0 |
Antigens, CD40/*metabolism | 3 | 6.0 |
B-Lymphocytes/*immunology/metabolism | 6 | 12.0 |
CD40 Ligand | 5 | 2.0 |
Cell Cycle/immunology | 2 | 6.0 |
Antigens, CD/immunology/metabolism | 3 | 5.0 |
T-Lymphocytes, Cytotoxic/*immunology | 5 | 0.0 |
Hematopoietic Stem Cell Mobilization/methods | 2 | 11.0 |
Recombinant Proteins/therapeutic use | 5 | 1.0 |
Antigens, Surface/metabolism | 5 | 4.0 |
Bone Marrow Cells/metabolism | 2 | 2.0 |
Liver/embryology | 2 | 6.0 |
Antigens, Differentiation, B-Lymphocyte/immunology | 4 | 7.0 |
Bone Marrow/immunology | 7 | 5.0 |
Spleen/immunology | 2 | 1.0 |
Antineoplastic Agents/*pharmacology | 5 | 0.0 |
Promoter Regions (Genetics) | 5 | 0.0 |
Dose-Response Relationship, Immunologic | 4 | 0.0 |
Drug Synergism | 4 | 0.0 |
Hematopoietic Cell Growth Factors/pharmacology | 8 | 10.0 |
Liver/*cytology/embryology | 2 | 28.0 |
Recombinant Fusion Proteins/pharmacology | 2 | 2.0 |
Cell Membrane/enzymology | 5 | 2.0 |
Rats, Wistar | 4 | 0.0 |
Ryanodine Receptor Calcium Release Channel/metabolism | 2 | 18.0 |
Immunoglobulins, Light-Chain/*genetics | 2 | 16.0 |
Hematopoietic Stem Cell Transplantation | 9 | 5.0 |
Hematopoietic Stem Cells/cytology/*drug effects | 3 | 5.0 |
Leukocytes, Mononuclear/cytology/metabolism | 2 | 12.0 |
Membrane Proteins/*metabolism | 2 | 0.0 |
HIV Infections/*drug therapy/*immunology | 4 | 7.0 |
HIV Protease Inhibitors/*therapeutic use | 5 | 4.0 |
Anti-HIV Agents/administration & dosage/*therapeutic use | 2 | 4.0 |
Cell Survival/immunology | 2 | 3.0 |
Immunoglobulins/biosynthesis | 5 | 4.0 |
Pokeweed Mitogens/pharmacology | 2 | 2.0 |
NADP/*metabolism | 2 | 6.0 |
Antigens, CD56/*metabolism | 2 | 14.0 |
Gene Rearrangement, B-Lymphocyte, Heavy Chain | 3 | 4.0 |
Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 6 | 7.0 |
Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 2 | 6.0 |
Tumor Stem Cells/*immunology/pathology | 2 | 40.0 |
Antigens, CD28/*metabolism | 4 | 3.0 |
Cell Adhesion | 9 | 0.0 |
*Multiple Myeloma/genetics/immunology/pathology | 3 | 100.0 |
Translocation, Genetic/*genetics | 2 | 0.0 |
Antigens, Thy-1/analysis | 4 | 28.0 |
Hematopoietic Stem Cells/*metabolism | 10 | 7.0 |
Receptors, Antigen, T-Cell/*metabolism | 2 | 1.0 |
Immunoglobulins, kappa-Chain/analysis | 2 | 9.0 |
Lymphocytosis/*pathology | 2 | 66.0 |
Multiple Myeloma/pathology | 3 | 37.0 |
Carrier Proteins/biosynthesis | 4 | 6.0 |
Antibodies, Viral/*blood | 2 | 4.0 |
Antigens, Viral/immunology | 2 | 1.0 |
Herpesvirus 4, Human/isolation & purification/*physiology | 2 | 50.0 |
Receptors, Tumor Necrosis Factor, Type I | 2 | 0.0 |
Tumor Markers, Biological/*blood | 3 | 0.0 |
Antigens, CD57/analysis | 2 | 4.0 |
Antigens, Differentiation, T-Lymphocyte/*analysis | 7 | 3.0 |
HIV-1/*physiology | 4 | 0.0 |
Antigens, CD/*genetics | 3 | 1.0 |
Introns | 3 | 0.0 |
Membrane Glycoproteins/*genetics | 4 | 0.0 |
*Polymorphism, Genetic | 2 | 0.0 |
Polymorphism, Restriction Fragment Length | 3 | 0.0 |
CD8-Positive T-Lymphocytes/cytology/*immunology | 2 | 7.0 |
Culture Media, Serum-Free | 3 | 0.0 |
Epitopes, T-Lymphocyte/*immunology | 2 | 3.0 |
T-Lymphocyte Subsets/cytology/immunology | 2 | 11.0 |
Interphase | 4 | 2.0 |
Chromosomes, Human, Pair 7 | 2 | 1.0 |
Proto-Oncogene Protein c-kit/*metabolism | 5 | 10.0 |
RNA, Messenger/genetics | 7 | 0.0 |
*Aneuploidy | 4 | 4.0 |
*Bone Marrow Transplantation | 5 | 1.0 |
Germinal Center/*physiology | 2 | 40.0 |
Cell Survival/drug effects | 3 | 0.0 |
Hematopoietic Stem Cells/*drug effects/immunology | 3 | 60.0 |
Stem Cell Factor/*pharmacology | 2 | 3.0 |
Antigens, Differentiation, Myelomonocytic/blood | 2 | 12.0 |
Macrophages/cytology | 2 | 2.0 |
Mast Cells/*cytology/immunology | 2 | 66.0 |
Multiple Myeloma/*immunology | 8 | 21.0 |
Plasma Cells/immunology | 5 | 18.0 |
Bone Marrow Cells | 18 | 4.0 |
Feasibility Studies | 4 | 1.0 |
*Hematopoietic Stem Cell Mobilization | 2 | 3.0 |
Retroviridae/genetics | 3 | 0.0 |
*Transfection | 3 | 1.0 |
*Leukapheresis | 3 | 8.0 |
Leukemia, Lymphocytic, Acute/immunology | 3 | 27.0 |
Germinal Center/immunology | 2 | 16.0 |
Antigens, CD28/*immunology | 3 | 2.0 |
Switzerland | 2 | 2.0 |
Viremia/immunology | 2 | 10.0 |
Antigens, Neoplasm/blood | 3 | 14.0 |
DNA, Neoplasm/*analysis | 4 | 2.0 |
Drug Combinations | 2 | 0.0 |
Granulocytes/metabolism | 2 | 5.0 |
Hematopoietic Stem Cells/*cytology/metabolism | 2 | 8.0 |
Fetus/*immunology | 3 | 6.0 |
Genetic Vectors | 3 | 0.0 |
Chromosome Disorders | 6 | 1.0 |
Plasma Cells/*metabolism | 2 | 16.0 |
Chromosome Mapping | 7 | 0.0 |
Antigens, Differentiation, B-Lymphocyte/metabolism | 3 | 5.0 |
Antigens, Surface/*metabolism | 2 | 3.0 |
HIV Seronegativity/immunology | 2 | 3.0 |
Homosexuality | 2 | 1.0 |
Apoptosis/*drug effects | 3 | 0.0 |
Multiple Myeloma/blood/*immunology | 2 | 22.0 |
Nuclear Proteins/analysis | 3 | 1.0 |
Retinoids/*pharmacology | 3 | 5.0 |
Signal Transduction/drug effects/*immunology | 2 | 5.0 |
Leukemia, Plasmacytic/*diagnosis/pathology | 2 | 100.0 |
Receptors, Lymphocyte Homing/*biosynthesis | 2 | 20.0 |
Syndrome | 2 | 0.0 |
Antigens, CD/immunology/*metabolism | 6 | 12.0 |
Antigens, CD3/*metabolism | 2 | 4.0 |
HIV Seronegativity | 4 | 2.0 |
Antigens, CD4/*metabolism | 2 | 0.0 |
T-Lymphocytes/*immunology/*virology | 2 | 20.0 |
Membrane Glycoproteins/metabolism | 4 | 0.0 |
Bucladesine/pharmacology | 3 | 1.0 |
Signal Transduction/*immunology | 8 | 2.0 |
Adenosine Diphosphate Ribose/metabolism | 4 | 7.0 |
Adenosine Diphosphate Ribose/*analogs & derivatives/physiology | 2 | 100.0 |
Antigens, Differentiation/genetics/physiology | 2 | 33.0 |
Second Messenger Systems/*physiology | 2 | 7.0 |
Cell Count/methods | 2 | 3.0 |
Mitotic Index | 2 | 1.0 |
Neoplasm Proteins/*analysis | 2 | 0.0 |
Lymphatic Metastasis | 3 | 0.0 |
Injections, Subcutaneous | 2 | 0.0 |
Lamivudine/*therapeutic use | 2 | 5.0 |
Reverse Transcriptase Inhibitors/*therapeutic use | 3 | 2.0 |
Zidovudine/*therapeutic use | 3 | 1.0 |
Antigens, CD45/*metabolism | 2 | 6.0 |
Hematopoiesis/physiology | 2 | 4.0 |
*Calcium Signaling | 2 | 4.0 |
HLA-DR Antigens/*immunology | 3 | 2.0 |
HIV Infections/*blood/immunology | 2 | 7.0 |
HIV Infections/blood/*drug therapy/*immunology | 2 | 40.0 |
Lymphocyte Activation/*drug effects | 3 | 0.0 |
Zidovudine/therapeutic use | 3 | 1.0 |
*Blood Transfusion, Autologous | 2 | 8.0 |
Hematologic Neoplasms/*therapy | 2 | 7.0 |
Whole-Body Irradiation | 2 | 2.0 |
Cell Cycle/drug effects | 3 | 0.0 |
Tretinoin/*pharmacology | 17 | 5.0 |
Gestational Age | 4 | 0.0 |
Thymus Gland/cytology | 2 | 2.0 |
Antigens, CD56/analysis | 6 | 9.0 |
Cytokines/pharmacology | 5 | 1.0 |
Killer Cells, Natural/*cytology | 2 | 8.0 |
Fetal Blood/cytology/immunology | 3 | 8.0 |
Erythrocyte Membrane/metabolism | 2 | 3.0 |
Guanosine Diphosphate Sugars/metabolism | 2 | 100.0 |
Membrane Glycoproteins/*metabolism | 4 | 0.0 |
Proteolipids/metabolism | 2 | 8.0 |
Cell Line, Tumor | 8 | 0.0 |
Leukemia/*pathology | 2 | 4.0 |
Antigens, CD/*analysis/biosynthesis | 3 | 25.0 |
Monocytes/immunology | 3 | 0.0 |
Tissue Distribution | 5 | 0.0 |
Dogs | 2 | 0.0 |
Structure-Activity Relationship | 3 | 0.0 |
Leukemia, Myeloid/*pathology | 3 | 5.0 |
Homosexuality, Male | 4 | 4.0 |
HIV-1/*growth & development | 2 | 3.0 |
beta 2-Microglobulin/analysis | 5 | 3.0 |
Antigens, CD4/analysis | 10 | 2.0 |
Calibration | 2 | 1.0 |
Microspheres | 3 | 1.0 |
Reference Standards | 4 | 1.0 |
Antigen-Antibody Reactions | 2 | 0.0 |
Antigens, CD8/analysis | 9 | 3.0 |
Fluorescein-5-isothiocyanate | 3 | 2.0 |
Lymphocyte Subsets | 9 | 4.0 |
Blood Preservation | 3 | 4.0 |
Antigens, CD4/*analysis | 5 | 3.0 |
HIV Infections/*blood | 2 | 4.0 |
Antigens, CD/*genetics/metabolism | 2 | 4.0 |
Antigens, Differentiation/*genetics/metabolism | 2 | 22.0 |
COS Cells | 4 | 0.0 |
Exons | 5 | 0.0 |
Multienzyme Complexes/*genetics/metabolism | 2 | 20.0 |
NAD+ Nucleosidase/*genetics/metabolism | 2 | 100.0 |
Polymorphism, Single-Stranded Conformational | 2 | 0.0 |
Leukemia, T-Cell, Chronic/*immunology | 2 | 40.0 |
Multiple Myeloma/*blood | 5 | 20.0 |
Adenosine Diphosphate Ribose/*analogs & derivatives/chemistry | 2 | 100.0 |
Fluorescence Polarization | 2 | 3.0 |
Niacinamide/pharmacology | 2 | 25.0 |
Spectrometry, Fluorescence | 3 | 0.0 |
Macromolecular Substances | 6 | 0.0 |
Hematopoietic Stem Cells/immunology/*physiology | 3 | 20.0 |
Proto-Oncogene Proteins/biosynthesis | 3 | 1.0 |
Lymphocyte Culture Test, Mixed | 2 | 0.0 |
Antigens, Surface/analysis | 11 | 2.0 |
Immunoglobulins/*biosynthesis | 3 | 6.0 |
Antiviral Agents/therapeutic use | 3 | 2.0 |
Blood Platelets/*enzymology | 2 | 2.0 |
Collagen/pharmacology | 2 | 1.0 |
Thrombin/pharmacology | 2 | 0.0 |
Antigens, CD3/*immunology | 2 | 1.0 |
Hydrogen-Ion Concentration | 5 | 0.0 |
Temperature | 3 | 0.0 |
Leukocytes/immunology | 2 | 1.0 |
RNA, Messenger/genetics/metabolism | 2 | 0.0 |
T-Lymphocytes/*immunology/metabolism | 2 | 1.0 |
Gene Amplification | 2 | 0.0 |
*Proto-Oncogenes | 2 | 0.0 |
*Transcription Factors | 2 | 0.0 |
*Drug Resistance, Neoplasm | 2 | 1.0 |
Adenosine Diphosphate Ribose/*analogs & derivatives/biosynthesis/blood | 2 | 100.0 |
Linkage (Genetics) | 2 | 0.0 |
X Chromosome | 4 | 0.0 |
Gene Expression Regulation, Neoplastic/drug effects | 3 | 0.0 |
Aneuploidy | 3 | 1.0 |
Paraproteinemias/*immunology | 2 | 10.0 |
B-Lymphocytes/immunology/*pathology | 2 | 7.0 |
Cell Transformation, Neoplastic | 3 | 0.0 |
Down-Regulation/physiology | 3 | 3.0 |
HLA Antigens/immunology | 2 | 1.0 |
Major Histocompatibility Complex/immunology | 2 | 4.0 |
Membrane Glycoproteins/immunology | 3 | 1.0 |
Antigens, CD/isolation & purification/*metabolism | 2 | 50.0 |
Chromatography, Affinity | 3 | 0.0 |
Molecular Weight | 5 | 0.0 |
Peptide Mapping | 2 | 0.0 |
Hamsters | 3 | 0.0 |
HLA-DR Antigens/*metabolism | 4 | 6.0 |
Leukemia/*immunology | 2 | 5.0 |
Multiple Myeloma/*genetics/pathology | 3 | 15.0 |
Endocytosis | 3 | 0.0 |
Immunoglobulins, Fab/immunology | 3 | 2.0 |
Tetradecanoylphorbol Acetate/pharmacology | 10 | 0.0 |
Antigens, CD3/*analysis | 2 | 6.0 |
Killer Cells, Natural/immunology | 12 | 2.0 |
Lymphocyte Subsets/*immunology | 8 | 6.0 |
Antigens, CD8/*analysis | 8 | 11.0 |
T-Lymphocytes/immunology/*physiology | 2 | 3.0 |
B-Lymphocytes/cytology/immunology | 2 | 6.0 |
Fetal Blood/*cytology/*immunology | 3 | 50.0 |
Killer Cells, Natural/cytology/immunology | 2 | 11.0 |
T-Lymphocytes/cytology/immunology | 2 | 2.0 |
DNA/analysis | 6 | 0.0 |
Protein Binding/immunology | 3 | 1.0 |
T-Lymphocytes, Cytotoxic/*immunology/metabolism | 2 | 5.0 |
Calcium/physiology | 2 | 0.0 |
Cell Adhesion Molecules/physiology | 3 | 3.0 |
Recombinant Proteins | 3 | 0.0 |
Superoxides/metabolism | 2 | 0.0 |
Tretinoin/pharmacology | 9 | 2.0 |
Retroviridae/*genetics | 2 | 1.0 |
Herpesvirus 4, Human/physiology | 2 | 6.0 |
Virus Replication/immunology | 2 | 3.0 |
Interleukin-6/pharmacology | 8 | 2.0 |
Multiple Myeloma/metabolism/*pathology | 2 | 10.0 |
*Chromosomes, Human, Pair 11 | 2 | 0.0 |
Antibodies, Monoclonal/*biosynthesis | 2 | 5.0 |
Antigens, CD40/*physiology | 2 | 5.0 |
Interleukin-4/physiology | 3 | 7.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 3 | 0.0 |
Epirubicin/administration & dosage | 2 | 5.0 |
Granulocyte Colony-Stimulating Factor/*administration & dosage | 4 | 14.0 |
CD8-Positive T-Lymphocytes/pathology | 2 | 4.0 |
Antigens, CD95/*metabolism | 2 | 1.0 |
Immunoglobulin G/metabolism | 6 | 3.0 |
Interleukin-6/metabolism | 2 | 0.0 |
Stem Cells/pathology | 2 | 10.0 |
Antigens, CD19/metabolism | 4 | 16.0 |
Cell Line, Transformed | 9 | 0.0 |
Herpesvirus 4, Human | 5 | 3.0 |
Protein-Tyrosine Kinase/*metabolism | 3 | 0.0 |
Receptors, Antigen, B-Cell/physiology | 2 | 6.0 |
Cell Adhesion Molecules/*biosynthesis | 4 | 4.0 |
Hodgkin Disease/*therapy | 2 | 22.0 |
Lymphoma, Non-Hodgkin/*therapy | 3 | 27.0 |
Antigens, CD/*biosynthesis | 13 | 6.0 |
Killer Cells, Natural/immunology/*pathology | 4 | 30.0 |
Cytarabine/administration & dosage | 4 | 4.0 |
Mitoxantrone/administration & dosage | 3 | 11.0 |
Membrane Proteins/analysis | 2 | 1.0 |
Nucleoside Transport Proteins | 2 | 28.0 |
P-Glycoprotein/analysis | 2 | 8.0 |
Plasma Cells/*chemistry | 2 | 100.0 |
Multiple Myeloma/*pathology/therapy | 2 | 50.0 |
Pilot Projects | 2 | 0.0 |
NF-kappa B/metabolism | 2 | 0.0 |
Risk Assessment | 2 | 0.0 |
B-Lymphocytes/*cytology/immunology | 2 | 6.0 |
Cell Size | 4 | 1.0 |
Centrifugation | 3 | 4.0 |
Antigens, Differentiation/analysis/*immunology | 2 | 25.0 |
HLA-DR Antigens/analysis/immunology | 2 | 10.0 |
Survivors | 3 | 3.0 |
Antigens, Differentiation, B-Lymphocyte/*metabolism | 3 | 8.0 |
Lymphocytes/metabolism | 4 | 1.0 |
Plasma Cells/metabolism | 2 | 15.0 |
Culture Techniques | 2 | 0.0 |
Stromal Cells/*metabolism | 2 | 5.0 |
Aplysia/enzymology/*genetics | 2 | 100.0 |
Membrane Glycoproteins/chemistry/*genetics | 2 | 5.0 |
Receptors, Interleukin-6 | 4 | 4.0 |
Transplantation, Heterologous | 6 | 0.0 |
Antigens, Differentiation, Myelomonocytic/analysis | 7 | 1.0 |
Bone Marrow/*pathology | 5 | 3.0 |
Leukemia, Lymphocytic, Acute/genetics/*pathology | 2 | 66.0 |
Chromosomes, Human, Pair 9 | 2 | 1.0 |
Hematopoietic Stem Cells/*pathology | 4 | 5.0 |
RNA, Neoplasm/genetics | 3 | 0.0 |
Receptors, Antigen, T-Cell/analysis | 4 | 3.0 |
Endothelium, Vascular/*cytology | 2 | 1.0 |
Cell Nucleus/metabolism | 2 | 0.0 |
Leukemia, T-Cell/*pathology | 2 | 20.0 |
HIV Envelope Protein gp120/metabolism/*pharmacology | 2 | 22.0 |
*Cell Separation | 2 | 14.0 |
N-Glycosyl Hydrolases | 2 | 50.0 |
Antigens, Differentiation/immunology/*metabolism | 6 | 54.0 |
N-Glycosyl Hydrolases/immunology/*metabolism | 6 | 100.0 |
Proto-Oncogene Proteins/*metabolism | 5 | 0.0 |
1-Phosphatidylinositol 3-Kinase | 4 | 2.0 |
Phosphotransferases (Alcohol Group Acceptor)/*metabolism | 2 | 2.0 |
Gene Expression Regulation, Leukemic | 2 | 2.0 |
Retinoid X Receptors | 2 | 0.0 |
Tumor Cells, Cultured/drug effects | 2 | 0.0 |
Biopterin/analogs & derivatives/blood | 2 | 4.0 |
Neopterin | 2 | 2.0 |
Pregnancy/*immunology | 2 | 3.0 |
HLA-DR Antigens/*analysis | 10 | 5.0 |
Leukocytes, Mononuclear/cytology/immunology | 4 | 9.0 |
Granulocyte Colony-Stimulating Factor/therapeutic use | 2 | 3.0 |
*Bone Marrow Cells | 28 | 10.0 |
Hematopoietic Stem Cells/*cytology/drug effects | 3 | 4.0 |
Aplysia | 5 | 55.0 |
N-Glycosyl Hydrolases/metabolism | 9 | 52.0 |
Bone Marrow/immunology/pathology | 3 | 8.0 |
N-Glycosyl Hydrolases/analysis | 17 | 62.0 |
Severe Combined Immunodeficiency/*immunology | 2 | 28.0 |
*Transplantation, Heterologous | 3 | 4.0 |
Microscopy, Immunoelectron | 2 | 0.0 |
N-Glycosyl Hydrolases/*analysis | 12 | 85.0 |
Bone Marrow/metabolism | 4 | 3.0 |
In Situ Hybridization | 5 | 0.0 |
*Oncogenes | 2 | 0.0 |
HLA-DR Antigens/biosynthesis | 7 | 7.0 |
Interleukin-2/*pharmacology | 3 | 1.0 |
N-Glycosyl Hydrolases/biosynthesis | 6 | 85.0 |
Receptors, Immunologic/physiology | 2 | 1.0 |
Chromosomes, Human, Pair 15 | 2 | 1.0 |
Chromosomes, Human, Pair 17 | 3 | 0.0 |
Cytokines/*biosynthesis/genetics | 2 | 2.0 |
HLA Antigens/analysis | 2 | 0.0 |
Bone Marrow/immunology/*pathology | 3 | 17.0 |
N-Glycosyl Hydrolases/*biosynthesis | 3 | 75.0 |
Immunoglobulin G/biosynthesis | 6 | 3.0 |
Germinal Center/*cytology/immunology | 2 | 28.0 |
Cell Separation/instrumentation/methods | 2 | 50.0 |
Interleukin-3/pharmacology | 5 | 1.0 |
Blood Cell Count/drug effects | 2 | 9.0 |
Immunoglobulin M/*immunology | 2 | 3.0 |
Immunologic Deficiency Syndromes/*immunology | 5 | 14.0 |
Intracellular Fluid/chemistry | 2 | 13.0 |
Gene Rearrangement, B-Lymphocyte, Light Chain | 2 | 9.0 |
RNA, Viral/analysis | 3 | 1.0 |
Cyclic ADP-Ribose/metabolism | 3 | 100.0 |
Antigens, CD34/*biosynthesis | 2 | 4.0 |
*Chromosomes, Human, Pair 4 | 2 | 0.0 |
Adenosine Triphosphate/*metabolism | 2 | 2.0 |
Escherichia coli/genetics | 2 | 0.0 |
Linear Models | 2 | 0.0 |
Lymph Nodes/cytology | 2 | 4.0 |
N-Glycosyl Hydrolases/*immunology | 5 | 100.0 |
Bone Marrow/*physiology | 2 | 11.0 |
Selection (Genetics) | 2 | 1.0 |
Mutagenesis | 2 | 0.0 |
Data Interpretation, Statistical | 2 | 0.0 |
Multiple Myeloma/*immunology/pathology | 2 | 11.0 |
Plasma Cells/*immunology/metabolism | 2 | 100.0 |
Lymphoma, Non-Hodgkin/immunology/pathology | 2 | 20.0 |
Monocytes/cytology | 3 | 2.0 |
Receptors, Immunologic/metabolism | 2 | 1.0 |
N-Glycosyl Hydrolases/chemistry/*metabolism | 3 | 50.0 |
*Renal Dialysis | 2 | 0.0 |
N-Glycosyl Hydrolases/*metabolism | 9 | 40.0 |
Leukemia, Myeloid, Chronic/immunology/*pathology | 2 | 22.0 |
Receptors, Antigen, T-Cell, alpha-beta/*genetics | 2 | 2.0 |
Species Specificity | 3 | 0.0 |
Spleen/pathology | 3 | 4.0 |
Cell Movement | 3 | 0.0 |
Antigens, CD34/biosynthesis | 4 | 4.0 |
Antigens, CD19/*analysis | 2 | 16.0 |
Hematopoietic Stem Cells/*chemistry | 3 | 11.0 |
Diploidy | 2 | 1.0 |
Glutathione/pharmacology | 2 | 5.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/*pharmacology | 2 | 1.0 |
Antigens, CD/analysis/immunology | 4 | 8.0 |
Antigens, Differentiation/*analysis/*immunology | 2 | 100.0 |
Hematopoiesis/*drug effects | 2 | 2.0 |
Cytoplasm/immunology | 4 | 4.0 |
HIV Infections/*immunology/pathology | 2 | 6.0 |
Lymph Nodes/metabolism | 2 | 3.0 |
Interleukin-6/secretion | 2 | 3.0 |
Herpesvirus 4, Human/genetics | 3 | 4.0 |
Growth Inhibitors/*pharmacology | 2 | 1.0 |
*Herpesvirus 4, Human | 4 | 11.0 |
Morpholines/pharmacology | 2 | 0.0 |
B-Lymphocytes/cytology/drug effects/*immunology | 2 | 20.0 |
Decidua/*cytology/*immunology | 2 | 100.0 |
Killer Cells, Natural/*metabolism | 2 | 3.0 |
Pregnancy Trimester, First | 3 | 1.0 |
Centrifugation, Density Gradient | 2 | 0.0 |
Glycosylphosphatidylinositols | 2 | 3.0 |
Cell Differentiation/*drug effects | 2 | 1.0 |
Fusion Proteins, bcr-abl/genetics | 2 | 4.0 |
Tumor Stem Cells/*pathology | 3 | 11.0 |
Hematopoietic Stem Cells/drug effects/*metabolism | 2 | 10.0 |
6-Mercaptopurine/administration & dosage | 2 | 10.0 |
Daunorubicin/administration & dosage | 2 | 5.0 |
Leukemia, B-Cell, Chronic/*immunology/pathology | 2 | 12.0 |
N-Glycosyl Hydrolases/*physiology | 2 | 40.0 |
Lymphocytes/*immunology/pathology | 2 | 10.0 |
Aging/*immunology | 2 | 1.0 |
Antigens, CD3/blood | 2 | 6.0 |
Immunosuppressive Agents/*pharmacology | 2 | 0.0 |
Etoposide/administration & dosage | 2 | 1.0 |
Receptors, Antigen, T-Cell, gamma-delta/genetics | 2 | 8.0 |
Protein Processing, Post-Translational | 2 | 0.0 |
Interleukin-3/*pharmacology | 4 | 3.0 |
Multiple Myeloma/*immunology/*pathology | 2 | 33.0 |
Leukocytes, Mononuclear/*immunology | 2 | 1.0 |
NAD+ Nucleosidase/*antagonists & inhibitors | 3 | 100.0 |
Antigens, CD45/*analysis | 4 | 8.0 |
Immunoglobulin A/metabolism | 2 | 3.0 |
Membrane Glycoproteins/biosynthesis | 2 | 1.0 |
N-Glycosyl Hydrolases/immunology | 5 | 83.0 |
Staining and Labeling/*methods | 2 | 10.0 |
Cell Differentiation/drug effects/physiology | 3 | 3.0 |
Immunoglobulins/physiology | 2 | 28.0 |
Antigens, CD19/biosynthesis | 2 | 16.0 |
Growth Substances/*pharmacology | 2 | 0.0 |
Leukemia | 2 | 2.0 |
Antigens, Differentiation/*analysis/immunology | 2 | 18.0 |
Proto-Oncogene Protein c-kit/analysis | 3 | 6.0 |
Radiation Chimera | 2 | 4.0 |
CD4-Positive T-Lymphocytes/*metabolism | 2 | 2.0 |
Cell Adhesion Molecules/biosynthesis | 3 | 3.0 |
Chromosomes, Human, Pair 11/genetics | 2 | 0.0 |
Chromosomes, Human, Pair 13/genetics | 2 | 3.0 |
Protein p53/genetics | 2 | 1.0 |
Antigens, CD28/*analysis | 2 | 10.0 |
Receptors, Antigen, T-Cell, gamma-delta/*analysis | 3 | 7.0 |
Antigens, Neoplasm/immunology | 2 | 1.0 |
Histocompatibility Testing | 3 | 0.0 |
Proto-Oncogene Proteins c-bcl-2 | 7 | 4.0 |
N-Glycosyl Hydrolases/*blood | 2 | 100.0 |
Immunoglobulins/analysis | 6 | 2.0 |
Lymphoma, B-Cell/genetics/immunology/*pathology | 2 | 50.0 |
Gene Expression Regulation, Leukemic/*drug effects | 2 | 5.0 |
Bone Marrow/drug effects | 3 | 4.0 |
Glycophorin/analysis | 2 | 14.0 |
Receptors, Antigen, T-Cell/genetics | 2 | 2.0 |
Antigens, CD8/immunology | 2 | 2.0 |
Fatigue Syndrome, Chronic/*immunology | 3 | 37.0 |
Lymphocytes/immunology | 6 | 1.0 |
Molecular Structure | 3 | 0.0 |
Antigens, CD/*biosynthesis/genetics | 2 | 3.0 |
Cercopithecus aethiops | 3 | 0.0 |
Endothelium, Vascular/*metabolism | 2 | 0.0 |
Plasmacytoma/immunology | 2 | 33.0 |
Antigens, CD4/immunology | 2 | 1.0 |
ADP-ribosyl Cyclase/biosynthesis | 3 | 50.0 |
Lymphoma, B-Cell/immunology | 2 | 11.0 |
Leukocytes/*immunology | 2 | 1.0 |
Cell Adhesion Molecules | 2 | 3.0 |
Mice, Transgenic | 2 | 0.0 |
Interleukin-6/*metabolism | 2 | 1.0 |
Receptors, Interleukin/*metabolism | 2 | 6.0 |
Tetradecanoylphorbol Acetate/*pharmacology | 2 | 0.0 |
Immunoglobulin G/*metabolism | 2 | 3.0 |
Antigens, CD27/*metabolism | 2 | 14.0 |
Lymphocytes/pathology | 3 | 3.0 |
Common Variable Immunodeficiency/*immunology | 2 | 13.0 |
*Gene Expression Regulation | 3 | 0.0 |
Lymphocyte Function-Associated Antigen-1/biosynthesis | 2 | 9.0 |
Antigens, CD19/blood | 2 | 15.0 |
Acquired Immunodeficiency Syndrome/*immunology/pathology | 2 | 13.0 |
*Kidney Transplantation | 2 | 0.0 |
HLA-DR Antigens/*biosynthesis | 3 | 10.0 |
Age Factors | 10 | 0.0 |
Antigens, CD56 | 5 | 7.0 |
Antigens, CD44 | 3 | 1.0 |
Dendritic Cells/*immunology | 2 | 0.0 |
Receptors, Cell Surface/immunology | 2 | 5.0 |
Antigens, CD19 | 8 | 4.0 |
Mercaptoethanol/pharmacology | 2 | 6.0 |
N-Glycosyl Hydrolases/*chemistry | 2 | 33.0 |
Binding Sites, Antibody | 3 | 0.0 |
Immunoglobulin Variable Region/immunology | 2 | 6.0 |
Immunotherapy/methods | 2 | 2.0 |
Multiple Myeloma/*therapy | 3 | 17.0 |
Leukemia, T-Cell, Acute/*drug therapy/immunology | 2 | 66.0 |
Blood Donors | 2 | 0.0 |
Sex Factors | 3 | 0.0 |
N-Glycosyl Hydrolases/*genetics | 2 | 7.0 |
Protein Engineering | 2 | 2.0 |
Antigens, Differentiation, B-Lymphocyte/*analysis | 5 | 8.0 |
Antigens, CD40 | 4 | 7.0 |
L-Selectin | 3 | 4.0 |
Receptors, Cell Surface/biosynthesis | 2 | 5.0 |
Receptors, Lymphocyte Homing/biosynthesis | 2 | 11.0 |
T-Lymphocytes/*cytology | 2 | 2.0 |
Antigens, Neoplasm/*immunology | 2 | 1.0 |
Plasma Cells/immunology/*physiology | 2 | 100.0 |
Antigens, CD/*biosynthesis/physiology | 2 | 40.0 |
*Proteins | 2 | 0.0 |
Serine Endopeptidases/genetics | 2 | 5.0 |
Antigens, CD/analysis/*blood | 2 | 40.0 |
Proto-Oncogene Protein c-kit | 5 | 6.0 |
Stem Cell Factor | 3 | 3.0 |
Apoptosis/genetics | 2 | 0.0 |
Antigens, CD7 | 4 | 3.0 |
Antigens, Differentiation, T-Lymphocyte/immunology | 3 | 1.0 |
Enterotoxins/*toxicity | 2 | 16.0 |
Superantigens/*toxicity | 2 | 50.0 |
Neoplasm Staging/*methods | 2 | 5.0 |
*Antigens, CD/analysis | 2 | 20.0 |
Interleukin-2/therapeutic use | 2 | 5.0 |
Myeloma Proteins/*analysis | 2 | 50.0 |
Hematopoietic Cell Growth Factors/*pharmacology | 2 | 4.0 |
Insulin/secretion | 3 | 5.0 |
Clone Cells/immunology | 2 | 1.0 |
Immunoglobulins/metabolism | 4 | 3.0 |
DNA Probes | 2 | 0.0 |
Lymphocytes/cytology | 2 | 2.0 |
Multiple Myeloma/genetics/*pathology | 2 | 50.0 |
Neprilysin/analysis | 3 | 5.0 |
Killer Cells, Natural/*pathology | 4 | 13.0 |
Interleukin-6/*physiology | 2 | 2.0 |
Antigens, Surface/*genetics | 2 | 3.0 |
Antigens, CD/analysis/*immunology | 2 | 5.0 |
Leukemia, B-Cell, Acute/diagnosis/*immunology | 2 | 100.0 |
ADP-ribosyl Cyclase/*biosynthesis | 4 | 100.0 |
Leukemia, B-Cell, Chronic/*immunology | 2 | 4.0 |
Pleural Effusion/pathology | 2 | 28.0 |
Ki-67 Antigen | 2 | 0.0 |
Lymph Nodes/*pathology | 3 | 3.0 |
Spleen/metabolism | 2 | 1.0 |
*Blood Donors | 3 | 2.0 |
Cytokines/*pharmacology | 2 | 0.0 |
Autoradiography | 2 | 0.0 |
CD4-Positive T-Lymphocytes/cytology/*immunology | 2 | 3.0 |
*Adenosinetriphosphatase | 2 | 2.0 |
Burkitt Lymphoma/*immunology | 2 | 10.0 |
Immunoglobulin M/*analysis | 2 | 4.0 |
Immunoglobulins, Surface/analysis | 2 | 4.0 |
Cytological Techniques | 2 | 5.0 |
Interleukin-2/biosynthesis | 3 | 0.0 |
Antigens, CD5 | 2 | 0.0 |
Antigens, Differentiation/analysis/immunology | 2 | 22.0 |
Phycoerythrin | 3 | 15.0 |
Gene Expression/drug effects | 4 | 0.0 |
Granulocytes/cytology | 2 | 4.0 |
Leukemia, Promyelocytic, Acute | 2 | 3.0 |
Antigens, CD8 | 2 | 0.0 |
T-Lymphocytes, Suppressor-Effector/immunology | 3 | 1.0 |
*Cell Transformation, Viral | 3 | 1.0 |
Hematopoiesis/drug effects | 4 | 5.0 |
Interleukins/*pharmacology | 2 | 2.0 |
Antigens, CD29 | 3 | 4.0 |
Postoperative Period | 2 | 0.0 |
T-Lymphocytes/*metabolism | 2 | 0.0 |
Interleukin-4/*pharmacology | 2 | 0.0 |
Antigens, CD11 | 3 | 3.0 |
Proto-Oncogene Proteins/*analysis | 2 | 1.0 |
HIV/*immunology | 2 | 1.0 |
HIV Infections/immunology | 2 | 2.0 |
Lymph Nodes/pathology | 2 | 0.0 |
Cell Differentiation/*physiology | 2 | 0.0 |
Epstein-Barr Virus Nuclear Antigens | 2 | 4.0 |
Cyclophosphamide/therapeutic use | 2 | 2.0 |
Antigens, CD1 | 2 | 2.0 |
Intercellular Adhesion Molecule-1 | 3 | 1.0 |
HIV Seropositivity/immunology | 2 | 2.0 |
Antigens, CD30 | 2 | 7.0 |
HLA-D Antigens/analysis | 2 | 3.0 |
Chromosomes, Human, Pair 11 | 4 | 1.0 |
B-Lymphocytes/*drug effects/immunology | 2 | 6.0 |
T-Lymphocytes/*drug effects/immunology | 2 | 2.0 |
Fetal Blood/*metabolism | 2 | 4.0 |
Antigens, Surface/immunology | 5 | 2.0 |
Antigens, CD20 | 4 | 5.0 |
Antigens, CD45 | 4 | 1.0 |
Schistosomiasis haematobia/*immunology | 2 | 33.0 |
Histocompatibility Antigens/analysis | 2 | 3.0 |
Interleukin-2/secretion | 3 | 4.0 |
Interleukin-4/secretion | 2 | 4.0 |
Antigens, CD3 | 2 | 0.0 |
Receptors, Antigen, T-Cell/*immunology | 2 | 1.0 |
Tumor Cells, Cultured/*pathology | 2 | 10.0 |
Antigen-Presenting Cells/*immunology | 2 | 1.0 |
Neprilysin | 2 | 2.0 |
Rosette Formation | 4 | 1.0 |
*Leukocyte Count | 2 | 3.0 |
Immune Tolerance/drug effects | 2 | 7.0 |
Lymphoma/*pathology | 2 | 9.0 |
Infectious Mononucleosis/blood/*immunology | 2 | 66.0 |
T-Lymphocytes | 2 | 0.0 |
ADP-ribosyl Cyclase/*antagonists & inhibitors | 2 | 100.0 |
Receptors, IgG | 2 | 1.0 |
Interleukin-4 | 2 | 2.0 |
Receptors, Fc/analysis | 2 | 3.0 |
Receptors, IgE | 2 | 3.0 |
Neoplasm Invasiveness | 2 | 0.0 |
Antigens, CD40/metabolism | 2 | 3.0 |
Membrane Proteins/metabolism | 2 | 0.0 |
Receptors, Antigen, B-Cell/metabolism | 2 | 4.0 |
CD8-Positive T-Lymphocytes/immunology/*metabolism | 2 | 12.0 |
Protein-Tyrosine Kinase/*genetics | 2 | 0.0 |
beta 2-Microglobulin/blood | 2 | 8.0 |
B-Lymphocytes/*metabolism/pathology | 2 | 18.0 |
ADP-ribosyl Cyclase/immunology/*metabolism | 2 | 100.0 |
ADP-ribosyl Cyclase/*blood | 2 | 100.0 |
Tretinoin/metabolism/pharmacology | 2 | 22.0 |
Bone Marrow Cells/immunology/pathology | 4 | 28.0 |
*Gene Expression Profiling | 2 | 0.0 |
HIV Infections/*immunology/metabolism | 2 | 16.0 |
Leukemia, B-Cell, Acute/*immunology | 2 | 33.0 |
Antigens, CD/genetics/*physiology | 2 | 5.0 |
ADP-ribosyl Cyclase/genetics/*physiology | 2 | 100.0 |
Chromosomes, Human, Pair 13 | 2 | 1.0 |
Leukemia, Lymphocytic, Chronic/*genetics/immunology/mortality | 2 | 100.0 |
